ALEXANDRA O'MALLEY: Open Payments
NPI 1356927198 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$477 in 21 payments from 11 companies in 2025. Trend: 2023 $30 · 2024 $782 · 2025 $477
Food & beverage: $477
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $84 |
| Alkermes, Inc. | 3 | $79 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Janssen Pharmaceuticals, Inc | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Almatica Pharma LLC | 1 | $18 |
Products named: VRAYLAR, ARISTADA, Auvelity, REXULTI, SPRAVATO, VIVITROL, Sunosi, COBENFY.
Industry payments across MA — which companies pay providers there.
